Related Experiment Videos
Soluble L-selectin levels predict survival in sepsis
Jakob B Seidelin1, Ole H Nielsen, Jens Strøm
1Department of Gastroenterology C, Herlev Hospital, University of Copenhagen, Denmark. jakse@herlevhosp.kbhamt.dk
Intensive Care Medicine
|November 5, 2002
Summary
Serum soluble L-selectin (sL-selectin) is a key predictor of sepsis survival. Low sL-selectin levels upon ICU admission indicate a higher risk of mortality within 12 months for sepsis patients.
Area of Science:
- Critical Care Medicine
- Immunology
- Biomarkers
Background:
- Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
- Identifying reliable prognostic factors for sepsis survival is crucial for patient management.
- Soluble L-selectin (sL-selectin) is involved in inflammatory processes and cell adhesion.
Purpose of the Study:
- To investigate the utility of serum soluble L-selectin (sL-selectin) as a prognostic biomarker in patients with sepsis.
- To determine if sL-selectin levels correlate with short-term and long-term survival outcomes in sepsis.
Main Methods:
- Prospective study involving 63 sepsis patients and 14 controls admitted to an intensive care unit (ICU).
- Serum sL-selectin levels were measured on ICU admission and 4 days later.
- Mortality data were collected at multiple time points up to 12 months post-admission.
Main Results:
- Sepsis patients exhibited significantly lower serum sL-selectin levels compared to healthy controls.
- Non-survivors of sepsis had markedly lower sL-selectin levels than survivors.
- A serum sL-selectin level below 470 ng/ml was identified as an indicator of increased 12-month mortality risk.
Conclusions:
- Serum sL-selectin serves as a significant predictor of survival in sepsis patients.
- Patients with low admission sL-selectin levels (<470 ng/ml) face a substantially higher risk of mortality.
- sL-selectin levels did not correlate with clinical severity scores (SAPS II) or microbial findings.